Navigation Links
iFuse Implant System(TM) to be Presented at Leading Minimally Invasive Spine Surgical Meetings
Date:4/27/2010

CUPERTINO, Calif., April 27 /PRNewswire/ -- SI-BONE, Inc. (Cupertino, California), a medical device company that is pioneering the use of a minimally invasive surgical (MIS) device to treat the sacroiliac (SI) joint today announced that iFuse initial post-market clinical experience will be presented at upcoming 2010 minimally invasive spine surgery meetings.

SI-BONE has been working with several well-known spine surgeons with experience in low back pathologies, who are early adopters of new MIS technologies.  These surgeons, including Steven Garfin, J. John Halki, Arnold Graham-Smith, Fred Geisler, Leonard Rudolf, David Polly, Michael Amaral and A. Nick Shamie, have been providing the Company clinical direction and feedback.  Separately, these surgeons are working on the submission of manuscripts and abstracts to spine society meetings and peer-reviewed journals.  Recently, Dr. Garfin presented details regarding SI joint disease, diagnosis and MIS treatment at the Mayo Spine Symposium in Hawaii and the Israeli Spine Society in April.  Upcoming iFuse presentations include the World Congress of Minimally Invasive Spine Surgery & Technologies (WCMISST) in Las Vegas May 31-June 4, 2010, the North American Spine Surgery (NASS) in Orlando on October 7, 2010 and World Congress of Low Back & Pelvic Pain in Los Angeles November 9-12, 2010.

"We're very pleased to have such a high interest from our colleagues in undertaking clinical evaluation and presentation of post-market clinical experience regarding SI joint pathology and the iFuse MIS procedure as a new option for patients," said Dr. Garfin.  He added, "I'm sure that these presentations will be instrumental in helping to increase awareness on diagnosis of SI joint problems, the treatment of patients non-operatively and with iFuse for those who have failed non-operative therapies."

According to Mark Reiley, MD, founder and Chief Medical Officer at SI-BONE, the iFuse post-market clinical experience appears to be very encouraging.  Dr. Reiley reported, "In the recently accepted submissions, the investigators report on more than 50 patients treated with iFuse. Sacroiliac joint syndromes are common and the accepted submissions reinforce the need for awareness that the SI joint can produce symptoms."

Dr. Reiley further commented, "We are honored that our colleagues have agreed to bring their extensive clinical experience and patient-centric focus to our scientific efforts and dedication to ongoing improvements in our technology.  We expect to benefit from their insights and expertise in understanding MIS SI Joint fusion as a frontline therapy for patients with unresolved low back symptoms refractory to conservative therapy.  We will continue to reach out to other spine surgeons and referring specialists to encourage clinical evaluation of iFuse, and we look forward to their further contributions."

J. J. Halki, MD, principal investigator from Northern Nevada Medical Center in Reno, commented that, "physiatrists need to have an outlet for these previously, unsatisfied SI joint patients.  In some patients with residual symptoms after hip arthroplasty or lumbar spine procedures, it may be the SI joint that is the symptom generator.  With the advent of the iFuse MIS procedure, the surgeon may now be able to successfully treat patients refractory to conservative therapy and effectively partner with non-operative pain specialists to offer patients new treatment solutions."  

In response to increasing awareness of SI Joint dysfunction as a debilitating symptom generator, SI-BONE, Inc. developed an innovative, patented, intramedullary implant to treat the SI Joint. The company is also planning a post-market multicenter study to determine its effect over time on SI Joint pathology and on symptoms associated with SI Joint dysfunction.  

The iFuse Implant System is a commercially available device in the US intended for fracture fixation of large bones and large bone fragments of the pelvis for conditions including sacroiliac joint disruptions and degenerative sacroiliitis.  The iFuse procedure uses a minimal incision for delivery and implantation of small, titanium implants.  The implants are coated with a porous plasma spray that acts as an interference surface, designed to help decrease implant motion.  These implants have substantial thickness and sophisticated metallurgy and are able to produce a much stronger construct than that of conventional pins or screws used to surgically fix boney structures.  This implant technology from SI-BONE has been previously used successfully in well over 1,000 cases of dysfunctional foot joints.

About SI-BONE, Inc.

SI-BONE, Inc. (Cupertino, California) is a leading spinal medical device company dedicated to the development of tools and products for diagnosing and treating patients with low back issues related to sacroiliac (SI) joint pathology.  The company has developed, and is manufacturing and marketing, less invasive approaches using implants for the treatment of SI Joint pathology.  SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices.


'/>"/>
SOURCE SI-BONE, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osteotechs MagniFuse(TM) Distributed to 68 U.S. Hospitals as Product Revenue Surpasses $1 Million
2. Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting
3. Osteotechs MagniFuse(TM) Technology Used in First U.S. Surgery
4. FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
5. FDA Approves First Totally Implanted Hearing System
6. Access MediQuip Announces Release of the Countrys First Centralized Recall Management Service(SM) for Implantable Devices
7. New Hip Implant Provides Personalized Fit
8. GelFix(TM) Posterior Spinal Distraction Implant Receives CE Mark
9. Ferring Pharmaceuticals and Gene Security Network Partner to Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology
10. American Heart Association Rapid Access Journal Report: Implanted Monitor Accurately Detects Heart Rhythm Disturbances
11. AHRQ and American College of Cardiology Collaborate On Study of Implantable Cardioverter Defibrillators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):